Brainsway (NASDAQ:BWAY – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $19.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 58.00% from the company’s previous close.
BWAY has been the subject of several other reports. Weiss Ratings lowered shares of Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, August 19th. Zacks Research downgraded shares of Brainsway from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. LADENBURG THALM/SH SH upped their price objective on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a report on Thursday, August 13th. New Street Research reaffirmed a “buy” rating on shares of Brainsway in a report on Friday, July 24th. Finally, Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Brainsway currently has an average rating of “Moderate Buy” and an average price target of $18.20.
View Our Latest Analysis on BWAY
Brainsway Stock Up 5.1%
BWAY traded up $0.59 during trading on Monday, hitting $12.03. The company’s stock had a trading volume of 66,949 shares, compared to its average volume of 150,779. The firm has a market cap of $484.01 million, a PE ratio of 27.33 and a beta of 1.29. The business’s 50 day simple moving average is $13.71 and its 200-day simple moving average is $14.64. Brainsway has a one year low of $7.14 and a one year high of $17.40.
Brainsway (NASDAQ:BWAY – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. Equities research analysts expect that Brainsway will post 0.33 EPS for the current fiscal year.
Institutional Investors Weigh In On Brainsway
Hedge funds have recently modified their holdings of the company. Tidal Investments LLC lifted its position in shares of Brainsway by 492.8% during the second quarter. Tidal Investments LLC now owns 89,248 shares of the company’s stock worth $1,384,000 after purchasing an additional 74,193 shares in the last quarter. HWG Holdings LP acquired a new stake in shares of Brainsway during the third quarter worth about $3,340,000. Renaissance Technologies LLC raised its holdings in Brainsway by 87.2% in the first quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after acquiring an additional 241,560 shares in the last quarter. Masters Capital Management LLC raised its holdings in Brainsway by 65.0% in the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after acquiring an additional 650,000 shares in the last quarter. Finally, Y.D. More Investments Ltd raised its holdings in Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after acquiring an additional 157,042 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.
Brainsway Company Profile
BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive treatments for brain disorders. Its primary technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is delivered through specialized treatment systems and helmet-like coils.
The company’s Deep TMS platform is used by healthcare providers in the treatment of major depressive disorder, obsessive-compulsive disorder and smoking addiction, subject to applicable regulatory clearances and local treatment guidelines.
Further Reading
- Five stocks we like better than Brainsway
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
- Insider Buying Is Rising at These 3 Regional Banks, But the Details Matter
- Illinois Tool Works Faces Headwinds—2 Alternatives Stand Out
- Luxury’s Middle Market Is Cracking—These 3 Stocks Could Win
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
